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1. Introduction
Glioblastoma multiforme (GBM) is a highly aggressive and malignant brain tumor that is
largely resistant to surgical, radiological, and chemotherapeutic intervention. It is character‐
ized as a WHO Grade IV astrocytoma with high infiltrative capacity into brain parenchyma,
resulting in debilitating cognitive deficits. Features such as diffuse tumor margins, high
vascularity, and necrosis are cardinal indications for GBM diagnosis [1]. Current treatment
regimens include a combination of surgery and radiotherapy, along with adjuvant temozolo‐
mide. This line of therapy has been successful in extending patient survival to 15 months [2].
However, the significant emotional and financial cost incurred by patients and their families
during this process can be devastating. All three approaches employ a shotgun approach with
nonspecific effects leading to reduced quality of life and increased burden of disease. Despite
advances in the management of many other tumor types, glioblastoma has not experienced
the same success and median survival still remains 15 months. An alarming 8% average
survival at 3 years stresses the urgent need for more effective treatments [3]. Emerging novel
therapeutics aim to manipulate the immune system for selective destruction of cancerous
tissue, while leaving healthy brain tissue undisturbed. These approaches offer promise for a
selective approach of tumor elimination with reduced side effects and improved quality of life.
However, immunotherapeutic success has also been limited, due to lack of understanding of
the influence of cancer cells on the immune system. Better understanding of the glioma and
immune interface will allow for more effective immune manipulations in order to generate
anti-tumor responses. Recent studies have identified intercellular signaling modalities as
critical components for tumor growth. Extracellular vesicles released from GBM cells have
been revealed to be potent modulators of the local environment to facilitate malignancy and
mitigate destruction of the tumor by immune cells. Specific mechanisms of vesicle-induced
changes are becoming more evident and offer novel targets for future therapies. Elucidating
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intracellular changes and signaling cascades that lead to phenotypic deviation of naïve
immune cells will reveal points of regulation to manipulate for tumor destruction. This chapter
aims to examine the multifaceted roles of GBM-derived extracellular vesicles on immune cells.
We will discuss the current state of knowledge about the mechanisms by which extracellular
vesicles alter the tumor microenvironment, along with new findings relating to transformation
of T cells by extracellular vesicles. Phenotypic changes, functional pathways, and protein
profiles of immune cells will be discussed to gain an understanding of the means of transfor‐
mation. These changes will also be assessed over time to highlight potential early markers of
tumor influence that may be used for diagnostic or prognostic application. Finally, we will
discuss considerations for new immunotherapies relating to immune cell transformation
induced by extracellular vesicles.
2. Tenacity of brain tumors
2.1. Failure of current therapies
2.1.1. Traditional therapies
Despite recent advancements in approaches to cancer treatment, GBM remains a complex and
problematic cancer to target. Diffuse borders of GBM tumors invade sensitive brain tissue and
make complete surgical resection particularly difficult. Incidentally, cancerous cells are left
behind, which allows the tumor to repopulate the resection cavity and enables recurrent tumor
growth. Radiation therapy is commonly utilized to eliminate portions of tumor remaining after
surgery and in recurrent settings. Although radiation has shown to provide survival benefit,
innocent bystander damage to nearby brain structures still remains a major obstacle in this
field. Newer technologies, including gamma knife surgery, allow for a more targeted approach
to access remaining tumor and reduce the risk of complications from a second surgery [4].
Despite this, damage to healthy tissue still occurs and the inability to target every cancerous
cell constituting the tumor remains problematic. The addition of the alkylating agent temo‐
zolomide to GBM treatment has extended overall survival and progression-free survival for
patients receiving surgical resection and radiation [5]. A multimodal approach in the treatment
of GBM offers the most promising outcome for patients. However, prognosis remains dismal
and quality of life is poor because these treatment options do not specifically target glioma
cells. In recent years, alternative approaches have been explored that more specifically isolate
cancerous cells and remove support from surrounding structures. Gliadel wafers implanted
into the surgical resection bed provide survival benefit by releasing anti-tumor agent, car‐
mustine, locally to target areas of infiltrating tumor. Since most GBM tumors will recur in a 2
cm margin surrounding the resection cavity, carmustine impregnated wafers are able to focus
on this area, while sparing other sensitive structures. The ease of implantation and regional
release of drug makes this method attractive, yet overall survival and quality of life is equal
to temozolomide alone, and wafers offer no benefit in recurrent settings [6]. Electric field
devices offer a novel approach to GBM destruction by emitting alternating electric fields to
slow and prevent tumor progression. However, incomplete understanding of the mechanism
by which electric fields can slow tumor growth has hindered success of this therapy. The
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noninvasive nature of electric field technology offers promise for enhanced quality of life and
ease of treatment delivery integrated into patient’s daily lives. Unfortunately, these devices
have shown to confer minimal benefit in survival over chemotherapy [7].
2.1.2. Monoclonal antibodies
Utilization of natural defense mechanisms offers the most potential to support the failing triad
of traditional therapies in GBM. One element of immunotherapy that has gained momentum
in recent years has been the use of monoclonal antibodies. Monoclonal antibodies offer
antigenic specificity and have been successful in controlling a variety of other cancers in
different stages including breast, lung, and melanoma [8]. The strength behind antibody
treatment lies in their ability to circulate to identify distant metastasis and specifically target
tumor-specific antigens. The first major obstacle for antibody therapy in GBM is delivery across
a selective blood-brain barrier and maintenance of the antibody binding pocket once penetra‐
tion is complete. Since GBM almost never metastasizes outside the cranial cavity, antibodies
must be able to access the tumor in situ by crossing over the blood-brain barrier easily. The
second major barrier for antibody therapy is the existence of few tumor-specific antigens on
the surface of GBM cells. Although some antigens have been identified to date, tumors have
been shown to adapt quickly to change expression of surface molecules in the face of antigen-
specific attack. Thus, even if these antigens have roles in aiding tumor progression, they are
not ideal targets because they are not necessary for tumor survival. In addition, the vast
heterogeneity of GBM tumors precludes a single target approach. Therefore, soluble factors
constituting the tumor microenvironment have been targeted. GBM tumors are highly
vascularized and release abundant amounts of vascular endothelial growth factor (VEGF) into
the external environment to induce local angiogenesis. Their high metabolic needs require
sustained nutrient delivery directly to the tumor site, so much that the cores of GBM tumors
contain areas of necrosis. Bevacizumab is a monoclonal antibody that binds and neutralizes
VEGFA in the brain tumor environment to reduce vascularization and limit nutrient delivery.
It is currently the only monoclonal antibody approved for use in recurrent GBM and is
implemented during various disease states in clinical trials [9]. Bevacizumab remains a passive
treatment option that has been successful in restricting tumor growth, but does not actively
kill cancerous cells. Some studies have suggested bevacizumab promotes development of
structurally competent blood vessels around the tumor, rather than the compromised leaky
vessels that typically grow in tumor sites [10]. This modification may help ameliorate symp‐
toms caused by cerebral edema, but does not slow nutrient delivery to GBM tumors. To date,
bevacizumab has conferred minimal overall survival benefit, although time to recurrence and
quality of life are reportedly improved [11]. Currently available treatment options offer a
variety of approaches that demonstrate clinical benefit, but none substantially extend survival
or decrease burden of disease for patients.
2.1.3. Tumor-specific immunotherapy
The heterogeneity and adaptability of GBM tumors needs to be met with a dynamic and
adaptable treatment strategy in order to maintain remission or eliminate the tumor altogether.
Manipulation of the adaptive immune system against GBM is the goal of future immuno‐
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therapies as a means to specifically identify cancerous cells for destruction. Vast molecular
differences between patients and within individual patient tumors have prevented identifi‐
cation of common components to target. New approaches employ ex vivo stimulation of
patient’s adaptive immune cells with their own tumor followed by injection of the activated
cells back into circulation. The goal of this approach is to initiate a level of immune stimulation
that will specifically target tumor antigens typically hidden in vivo, while protecting the patient
from autoimmune complications. The promise for initiation of an adaptive response stems
from identification of lymphocytes within GBM tissue during autopsies and the later under‐
standing of tumor specificity of these cells [12]. Although unable to eliminate the tumor, it
became clear that lymphocytes play a role in antitumor immunity. Activated lymphocytes
have a unique ability to migrate into brain parenchyma, thus ex vivo activation of the adaptive
immune response has been explored as a means of eliciting antitumor responses [13]. Varia‐
tions in type of tumor material, incubation conditions, adaptive cell types, and course of
treatment have been under rigorous investigation to optimize tumor destruction [12,14,15].
Tumor-specific antigens continue to be ideal targets, but tumors rarely rely on a single antigen,
and targeting overexpressed molecules could critically disrupt healthy cells that need those
antigens for survival. Molecular targets including EphA2, IL-13R2a, EGFRvIII and survivin
have been implicated in GBM progression and offer potential pathways and signaling
modalities for cellular immunotherapies to target [16–19]. Other potential sources of tumor
antigens include protein complexes, chaperones, RNA, and whole cell lysate [20]. These
approaches offer the benefit of stimulating a varied approach of tumor destruction because of
the immune cells’ innate ability to distinguish harmful from harmless. The potential for
response against multiple tumor antigens is greater with unbiased access to native tumor
material (antigens), thus the immune response has a better chance to elicit a multidimensional
attack against the heterogeneous GBM. The two primary approaches employing these
strategies include autologous T cell transfer and dendritic cell vaccines.
Autologous T cell transfer has been referred to as passive immunotherapy because the T cells
are stimulated ex vivo and reintroduced to the patient as antigen specific, activated cells.
Dendritic cell vaccines are an active type of therapy, in which dendritic cells are isolated from
the patient and pulsed with tumor antigen before reintroduction to the patient. The dendritic
cell then has the opportunity to present antigen in secondary lymphoid tissue to lymphocytes
in the ideal environment for activation. Both approaches continue to be studied in order to
identify the optimal approach to adaptive immune activation. Sipuleucel-T was the first FDA-
approved dendritic cell vaccine to exhibit survival benefit for any type of cancer and created
a new realm of potential for personal immunotherapy [21]. Utilization of this treatment
strategy for GBM is much more difficult, primarily because Sipuleucel-T relies on the presence
of a tumor antigen found on the subset of cells that respond well to treatment. Dendritic cell
vaccines for GBM currently under investigation in clinical trials employ differential antigenic
approaches in hope of producing an ideal cocktail [22–24]. However, passive and active
immunotherapies have not yet transformed the landscape of GBM due to complexity of the
disease. In fact, very few patients have exhibited tumor regression for any substantial period
of time [25]. A major obstacle that must be overcome when developing these immunogenic
responses is the immunosuppressive environment induced by GBM. Once the burden of
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immunosuppression is alleviated, immunotherapeutic strategies and their effectors will have
a better chance to infiltrate, identify, and kill cancerous cells.
2.2. Immune manipulation by gliomas
Malignant brain tumors are known to correspond with multiple mechanisms of immune
suppression. Although phenotypic changes have been well documented, specific mechanisms
inducing the alterations are less well understood. Presence of modified immune cells trans‐
formed by the tumor environment presents obstacles investigators need to consider when
developing new therapeutics utilizing the immune system. GBM cells can modulate their
external environment through release of soluble factors and expression of discrete molecules
on the cell surface. One soluble factor released from GBM that appears to have a major role in
tumor progression is transforming growth factor beta (TGFβ) [26]. TGFβ has a wide range of
effects capable of suppressing immune responses including inhibition of IL-2 receptor on T
cells, down regulation of MHC molecules on antigen presenting cells, and even neutralization
of activated lymphocytes entering the tumor environment ([26,27]. Inhibitors of TGFβ and
neutralizing antibodies have shown promise in mitigation of glioma growth and immune
suppression [28]. To further enhance immune suppression in the local environment, GBM
recruits and converts naïve cells. Transformation of monocytes to immunosuppressive
macrophages is one of the most significant changes GBM produces in the microenvironment.
Tumor associated macrophages (TAMs) can comprise of classically activated M1 macrophages
or alternatively actived M2. TAMs are predominantly of the M2 phenotype and are the most
common immune infiltrate in glioma [29]. Evidence has shown TAMs can comprise up to 40%
of the tumor mass in GBM, thus the suppressive roles are highly apparent [30]. Unlike M1
macrophages, M2 TAMs do not release proinflammatory and chemoattractive factors, but
instead aid in tumor progression and attenuate activity of infiltrating lymphocytes. TAMs can
arise from both circulating monocytes and resident microglia near the tumor site [31]. Gliomas
ability to tip the balance towards the M2 phenotype is important for tumor survival and
progression because of the protection conferred to evade immune destruction. TAMs isolated
from glioma express very little MHCII or costimulatory molecules CD80/86 and this phenotype
can be transferred to naïve monocytes introduced to the same cell culture media [29,32].
Impaired release of TNFα from glioma macrophages can also be transferred to naïve mono‐
cytes in cell culture, providing a regionally dependent inhibitory modulation of monocytes in
the GBM environment. In addition to reductions in TNFα release, TAMs actively suppress the
extracellular space by constitutively expressing immunosuppressive cytokines IL-10 and
TGFβ [33]. This active inhibition is supported by impaired cytotoxic capabilities of TAMs,
which generates a highly immunocompromised environment for GBM to grow [34]. Convert‐
ed TAMs further propagate the glioma environment through release of matrix metallopro‐
teases and growth factors for endothelial cells and tumor cells alike [35]. In order to remove
the inhibition caused by glioma TAMs, it will be necessary to tip the balance back towards the
classically activated M1 phenotype without causing autoimmunity or inflammatory conse‐
quences.
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Glioma patients exhibit varying degrees of lymphopenia, but often a great proportion of
remaining cells are regulatory T cells. This phenomenon has been observed in many types of
cancer and is thought to act as a driving force to maintain immunosuppression and propagate
tumor cells. It is unclear whether regulatory T cell production is driven primarily by MDSC,
tumor-released proteins, alternative signaling pathways, or carefully selected from the natural
T cell population. Anti-CD25 treatment options have shown benefit in the glioma setting,
which could help tilt the balance back towards an immunostimulatory environment [36].
Although the presence of a high concentration of regulatory T cells persists, some T cells have
the capability to become active and access the tumor bed. Tumor-infiltrating lymphocytes
(TILs) are antigen-specific lymphocytes capable of penetrating the blood-brain barrier in an
effort to confer immunity against a growing tumor. The presence of TILs in gliomas indicates
patients are not entirely tolerant to the tumor and attempt to mount a response against it, thus
yielding a more favorable prognosis for patients. However, the TILs do not respond to
mitogenic stimulation and proliferate very poorly in the face of a challenge [37]. The exact
origin and capabilities of TILs are not clear, but their ineffectiveness in tumor destruction
generates an opportunity to learn about transformation. Similar activation abilities have been
reported with B cells isolated from peripheral circulation of GBM patients, whereas immuno‐
globulin production is hindered when cells were stimulated [38].
3. Extracellular vesicles
3.1. Genesis
Extracellular vesicles (EVs) arise primarily from two distinct biogenesis pathways during
healthy and pathological conditions. Release of vesicles can occur by direct shedding of plasma
membrane (microvesicles) or though invagination of an endosome to form a multi-vesicular
body, which later fuses with the plasma membrane (exosomes) [39]. Distinction of origin is
controversial, since components of the plasma membrane and intracytosolic proteins are found
in both. Overlapping similarities in size, density, membrane proteins and morphology
suggests differential nomenclature is not necessary, but the specific difference between the
types of extracellular vesicles is not fully understood [40]. Shuttling of contents into EVs occurs
through random capture during vesicle formation and through selection based on mechanisms
remaining to be elucidated [41]. EVs are released by many cell types in normal and pathological
states, including lymphocytes, dendritic cells, neurons, reticulocytes, and tumors [42–46]).
These vesicles contain distinct cargo that resemble the cell from which they were released and
can be identified in circulating fluids such as urine, breast milk, plasma, saliva, cerebrospinal
fluid, and amniotic fluid [47]. EVs vary in size from 30-2,000 nm in diameter, which ultimately
dictates the amount of cargo they can carry. Enhanced release of extracellular vesicles from
cancer cells is an indicator that they may have a role in aiding in tumor progression [48]. Release
is further heightened in cancer cells exposed to radiation or hypoxic conditions [49,50]. Due
to their presence in these fluids and the specific signature they contain, EVs are ideal vehicles
for transfer of large amounts of information to modulate the external environment and signal
immune complexes.
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Abbreviations used in this figure. MVB: Multivesicular body
Figure 1. Release pathways for microvesicles and exosomes. Microvesicles are directly shed from the cellular mem‐
brane and capture contents by inclusion of nearby particles. Exosomes are formed through endosomal invaginations,
which form multivesicular bodies and fuse with the plasma membrane. Shuttling of exosomal contents is more selec‐
tive due to machinery available
3.2. Waste receptacles
EVs are responsible for a multitude of roles in intercellular communication. Enrichment of
discrete molecules suggests well-organized machinery dictates packaging of internal contents
before release. These small packets of information can be transferred long distances with
specificity for a recipient cell. However, their pleiotropic roles in a healthy setting are still not
fully understood. They were originally thought to be waste receptacles for cells lacking
lysosome machinery, since release was first identified during reticulocyte maturation [45].
Other studies have confirmed packaging of waste products into extracellular vesicles, along
with cytotoxic substances, including chemotherapeutic agents [51]. This evidence provides a
novel mechanism of drug resistance in cancerous cells and a potential target to induce
sensitivity to toxic drugs as well. Controlling drug transport can allow for delivery of chemo‐
therapeutic drugs at a lower concentration and provide increased efficacy. This is particularly
important in GBM in order to preserve healthy brain tissue typically damaged by toxic drugs
during treatment.
3.3. Immune response
In  addition  to  waste  disposal,  EVs  are  now  known  to  be  important  factors  in  antigen
presentation [42]. Immunostimulatory properties of EVs were first recognized by Raposo
et al. when they found MHC class II molecule enrichment on the surface of extracellular
vesicles  released  from  EBV-transformed  B  cells.  These  EVs  were  sufficient  to  elicit  an
antigen-specific T cell response. These data present a mechanism for rapid amplification of
specific immune response via presentation of peptides bound to MHC II molecules. Later
studies  confirmed  presence  of  co-stimulatory  molecules  on  the  surface  of  vesicles  and
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amplification of CD4+ and CD8+ responses through horizontal transfer of MHC II loaded
EVs from activated dendritic cells to maturing dendritic cells [52]. Further mechanisms of
immune activation by EVs include activation of NK cells and monocytes [53,54]. Extracellu‐
lar vesicles represent an ideal booster for immune responses, but also contain a kill switch
to dampen response and tightly regulate clearance of pathogens.  Activated lymphocytes
release EVs containing Fas ligand and APO2 ligand, which are both capable of inducing
cell  death [55].  It  is  postulated that release of cytotoxic components from activated cells
ensures  moderation  of  excessive  immune  responses  and  reduces  autoimmunity.  The
expression and composition of EVs in a normal immune response is highly controlled and
deliberate to ensure modulation at appropriate times.
3.4. Horizontal transfer of information
Intercellular communication via EVs allows for transfer of large amounts of information to
maintain homeostasis and normal physiological function. Some functions that have been
identified to date include tissue repair, stem cell regeneration, synaptic plasticity, neuronal
communication, and viral transmission [56–59]. EVs contain many components that resemble
the host cell, but also contain discrete pieces of information that may be useful for identification
of specific signaling capabilities. Valadi et al. first described packaging and transfer of
messenger RNA (mRNA) and microRNA (miRNA) in extracellular vesicles in 2007 [60]. EVs
from healthy mast cells were harvested and analyzed based on genetic content. Interestingly,
no DNA was found within EVs, which suggests they signal exclusively through epigenetic
changes and signaling mechanisms in the recipient cell. mRNA found in EVs released from
mast cells exhibited functionality and was found to be unique from the donor cell. This
discovery revealed a new complexity to intercellular communication by means of modifying
protein expression and gene regulation through horizontal transfer of packets of information.
Later studies have been able to identify distinct miRNA signatures in pathological conditions
not found in normal cells. These signatures have been well documented in ovarian cancers,
lung cancer, and GBM [61–63]. mRNA contained within GBM extracellular vesicles control a
variety of cellular functions to promote tumorigensis, including enhancement of angiogenic,
proliferative, and migratory pathways. Identification of cargo released from cancerous cells
offers critical information about components that are deliberately shuttled out of the cell,
possible influence on the local environment, and the potential to act as a peripheral biomarker
for diagnostic or prognostic applications. Genetic signatures are particularly valuable in the
brain tumor arena because of their ease of collection and sensitivity to identify of tumor
progression.
4. Tumor-derived EVs
4.1. EVs and tumor microenvironment
The Taylor group first identified release of tumor-derived EVs in 1979 [46]. Their seminal
study was met with antagonism because it was not believed that small particles like these
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could have any substantial effect on tumor propagation. Later studies confirmed these small
cellular  surrogates  could  act  locally  and  peripherally  and  their  bioactive  cargo  had
significance in the cancer setting [64,65]. EV cargo varies between cells and disease states
and the significance of inclusion of certain cargo is just beginning to be understood. EVs
are  capable  of  carrying  proteins,  lipids,  carbohydrates  and  nucleic  acids  in  endless
combinations. The restrictive size of the EV compartments dictates the amount of materi‐
al that can be packaged, thus tumor cells must selectively package opportunistic cargo to
facilitate  tumor progression.  Tumor specific  antigens MART1 and HER2/Neu have been
identified in EVs released from cells with respective mutations, implicating a role for EVs
in horizontal transfer of cancer promoting agents [48].  Much like transfer of viral  pepti‐
des,  EVs offer a mechanism to exponentially facilitate cancer progression through deliv‐
ery of disease-specific antigens. In the brain tumor setting, EVs have been shown to carry
and transfer the truncated EGFRvIII from GBM cells containing the mutation, to GBM cells
without the mutation [66]. EGFR mutant variant III may be associated with over 50% of
GBM tumors and indicates a negative prognosis for patients [67]. Rapid onset and growth
of this subset of GBM relies on the presence of EGFRvIII on the plasma membrane surface.
EV delivery of the mutated receptor to neighboring cells presents a partial explanation for
the relentless aggressiveness of these tumors. Besides tumor antigens, EVs also carry factors
to modify the extracellular environment to ensure tumor survival. Active matrix metallopro‐
tease (MMP) and other matrix remodeling enzymes have been identified as EV cargo and
are capable of compromising the rigidity of the extracellular matrix [68]. GBM tumors are
notoriously invasive around the borders of the tumor margin and it is likely that EVs play
a role in promoting invasion. Other factors carried by GBM EVs include angiogenic proteins
VEGF and IL-6, which aid in recruiting new blood vessels to the tumor site. Many other
pieces  of  cargo  have  been  identified  to  date,  but  the  functional  consequences  of  their
presence is  not clear.  Identification of  a tumor signature from tumor-derived EVs offers
promise  for  noninvasive  biopsy  type  analysis  and  could  aid  in  treatment  before  large
changes can be seen from imaging.
GBM  EVs  have  been  shown  to  participate  in  modulation  of  the  external  environment
through a variety of pathways, although specific molecules responsible for the changes are
not  known. Exogenous brain tumor EVs are capable of  enhancing proliferation of  GBM
cells  in a dose-dependent manner,  which generate a  positive feedback loop in  vivo  [69].
Thus, EVs are partially or largely responsible for rapid propagation of tumor cells. GBM
cells often induce their own proliferation through autocrine growth factor signaling, but
for cells that have not yet acquired the correct mutations, EVs offer a mechanism to promote
proliferation. In addition to proliferation, glioma EVs promote migration of tumor cells as
well [70]. Effectively, GBM tumors generate their own chemoattractive gradient away from
the core of the tumor towards the external environment. This process is further exacerbat‐
ed by radiation treatment,  as the GBM cells  release greater amounts of EVs and exhibit
enhanced migration towards  their  EVs [49].  Extensive  proteomic  studies  have  begun to
identify  material  responsible  for  some  of  these  changes.  Profiling  all  the  material  con‐
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tained within tumor-derived EVs and understanding the correct balance of information will
help to better characterize targets in the future.
4.2. Tumor-derived EVs and immune response
4.2.1. Cellular decoys
Extracellular vesicles are optimal vehicles for transfer of large amounts of information to
amplify  signaling  without  cell-to-cell  contact.  While  this  elegant  ability  can  amplify  an
immune response against  pathogens extremely rapidly,  it  can also be used as  a  mecha‐
nism  of  immune  manipulation  by  brain  tumor  cells.  The  pleiotropic  roles  of  tumor-
derived EVs on immune modulation are not fully understood and it is likely the effects in
the brain tumor environment may be unique compared to other tumor types. Many of the
studies conducted on tumor-derived EVs have occurred in vitro or using murine models,
but offer great insight about the modulatory capacities and potency of EVs. The immense
immunosuppressive roles of tumor-derived EVs reveal the importance of these signaling
modalities in the cancer setting. Modulation of both innate and adaptive immune respons‐
es undermines the immune system’s redundancy against harmful stimuli. Tumor EVs have
been shown to inhibit cytotoxic capabilities of natural killer (NK) cells that typically patrol
cellular surface antigens for danger signals [71] and presence of MHC. One of the mecha‐
nisms by which this occurs is through expression of danger signal MICA on the surface of
EVs released into the extracellular space. Binding of MICA on the surface of EVs by NK
cells prevents them from identifying the problematic cells and leads to inactivation of NK
cells through down regulation of MICA binding protein, NKG2D [72]. This process creates
difficulty for future attempts to activate this subset of NK cells in the presence of real tumor
and the continued release of tumor EVs as cellular decoys perpetuates inhibition. Similar‐
ly,  tumor  EVs  have  shown to  attenuate  humoral  immunity  by  binding  antigen-specific
antibodies and misguiding antibody-dependent cellular cytotoxicity away from the tumor
[73]. Expression of cell surface antigens on the surface of EVs introduces a unique obsta‐
cle for treatments targeting surface molecules. Immune cells and pharmacological agents
in development  will  have to  circumnavigate  the  decoy EVs to  specifically  access  tumor
cells.
4.2.2. Monocyte transformation
Another worrisome consequence of tumor EVs is their ability to restrict peripheral blood
monocytes from fully maturing to dendritic cells [74]. As a central hub bridging innate and
adaptive immunity, dendritic cells are critical for developing a specific and adaptable anti-
tumor response. The potential of immunotherapy relies heavily on the premise of selective
destruction by adaptive cells that have been fully educated by dendritic cells about tumor
antigens to target. Further evidence has revealed EVs can not only inhibit, but also promote a
transformation of monocytes towards a myeloid-derived suppressor cell (MDSC) phenotype.
MDSCs are critically important for facilitation of glioma growth, as discussed above, and can
comprise a large portion of glioma mass [29]. Tumor-derived EVs induce release of immuno‐
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suppressive factors from MDSC including TGFβ and PGE2 and also down regulate expression
of MHCII on monocyte cell surfaces, limiting activation potential [75,76].
4.2.3. Migratory capacity
The phenotypic changes of naïve immune cells exposed to tumor-derived EVs dictates the
functionality of the immune response to perpetuate tumor growth. One of the most important
functional consequences of tumor-derived EVs is the ability to alter migratory capacity of
PBMCs. Preliminary data from our group has demonstrated attenuation of migration of
mitogen-activated PBMCs moving towards glioma EVs (Figure 2). Migration is a necessary
component of activated PBMCs in order to properly activate and then destroy cells of interest.
When brain tumor EVs are present, this process is disrupted, which can prevent even the best
tumor-specific cells from reaching their targets. Interestingly, studies have demonstrated brain
tumor EVs can enhance tumor cell migration as discussed above. If glioma EVs truly facilitate
glioma migration while diminishing immune cell migration, it is possible similar pathways
are altered in both cell types. Better understanding of the exact mechanisms and pathways
involved will lead to pharmacologic targets that could reverse migratory effects. Because EVs
are packets of complex information, identification of a switch to reverse both processes
simultaneously will be challenging. However, immune cells can still enter the tumor site to
promote tumor growth, thus tumor-derived EVs do not entirely eliminate PBMC entry into
brain parenchyma. They may, however, select for immune cells that will only aid in tumor
progression, such as MDSCs, and limit migration of anti-tumor cells. This selective entry could
help explain why resident immune cells at the tumor site do not destroy the tumor and presents
a reason for the limited success of immunotherapies that do not address EV presence. Alter‐
natively, brain tumor EVs in peripheral circulation may prevent movement of activated
dendritic cells to secondary lymphoid tissue, severely compromising their ability to activate
an adaptive immune response.
Abbreviations used in this figure. PHA: Phytohemagglutinin; EVs: Extracellular Vesicles; PBMC: Peripheral Blood
Mononuclear Cell
Figure 2. Average migration of naïve PBMCs in the presence of mitogenic stimuli with or without extracellular vesi‐
cles. PBMCs were placed in the top of a migration chamber with PHA and the bottom chamber contained EVs or me‐
dia. The number of PBMCs that migrated to the bottom chamber was quantified after 24 hours. *=p < 0.01.
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4.3. Altered function of T cells
Aberrations of T cell phenotypes and functional capacities in the cancer setting have been
described,  but  specific  mechanisms of  alteration are  not  well  understood.  T cell  deficits
induced by tumor EVs are among the most important transformations necessary to protect
tumors from immune destruction. T cells cultured with tumor EVs exhibit reduced capacity
for interleukin-2 (IL-2) production, thus limiting the proliferative potential for activated T
cells [77]. In addition, tumor EVs can direct apoptosis of activated T cells though Fas/Fas-
L binding [78]. Expression of the Fas death signal on the surface of activated cells typical‐
ly is  used as a shut off  switch to prevent development of autoimmunity during normal
pathogenic clearance. Cancer cells are able to take advantage of the molecule expression
by releasing EVs containing Fas-L on their  surface  to  kill  threatening T cells  from afar.
Tumor EVs have also proven to be capable of suppressing mitogenic activation abilities of
naïve T cells in the ovarian cancer setting, exacerbating the attenuation of immunogenic
responses [79]. Although little work has been conducted analyzing the transformation of T
cells exposed to glioma exosomes, evidence exists that brain tumor EVs decrease quanti‐
ties of cytotoxic CD8 cells and inhibit interferon gamma release from remaining cells [80].
Our studies analyzing intracellular signaling cascades within naïve T cells exposed to glioma
EVs reveal aberrations of many signaling pathways seen in other cancer types, including
T cell receptor signaling (Figure 3). Analysis of just a few members of the signaling cascade
can predict the overall activation status of this pathway and isolate particular proteins of
interest to better understand how inhibition is occurring. Inhibition of the T cell receptor
cascade by EVs is  of  particular importance for immunotherapies,  which rely on genera‐
tion  of  antigen-specific  anti-tumor  cells.  Although  many  other  factors  in  the  tumor
microenvironment can alter T cell signaling, EVs appear to play a substantial role in creating
this change. Much like the effects of tumor EVs on monocytes, T cells can be inhibited and
converted to a suppressive phenotype [81]. Induction of regulatory T cells by tumor EVs
cultivates immunosuppressive factors in the tumor microenvironment to further prevent
activation of cells that may threaten tumor survival. Elevated levels of regulatory T cells
are common across many types of cancer and soluble factors pushing naïve cells towards
a  regulatory  phenotype  have  been  characterized  from  gliomas  [36].  Tumor  EVs  by
themselves are capable of inducing this transformation and may be an important factor to
target in order to prevent transformation.
4.4. Transformation of T cells over time
To date, no studies have analyzed the transformation of T cells in GBM over time or over
the  course  of  treatment.  Understanding  the  process  of  cellular  transformation  can  offer
information about response to treatment or act as a prognostic predictor before changes
can be seen on radiological imaging. Other research in the brain tumor EV field has been
able to correlate EV contents to the constitution of tumor cells, which will allow EVs to act
as a liquid biopsy to track treatment. Perhaps as important are the downstream consequen‐
ces of changing EV contents released from GBM and the amount of time needed to produce
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functional immune consequences. Better understanding of pathways affected earliest could
offer insight about which functions the tumors consider a priority to eliminate. Transforma‐
tion of stimulated T cells after exposure to brain tumor-derived EVs occurs quickly and we
have been able to characterize some of the important changes that occur in the first 72 hours
of glioma EV presence (Table 1). By analyzing protein expression profiles, we observed the
transformation of intracellular signaling pathways within naïve T-cells exposed to tumor-
derived extracellular vesicles at 72 hours compared to 2 hours. Apoptotic and developmen‐
tal  cascades  were  affected  in  the  early  stages,  whereas  migratory  pathways  become
increasingly dysregulated during later time points. These data parallel previous studies in
other  tumor  types,  but  here  we  are  able  to  identify  early  activation  of  apoptotic  path‐
ways that do not persist for a prolonged period of time in GBM. Instead, the EVs contin‐
ue to transform T cells  without killing them, with a focus on modification of migratory
capacity and cytotoxicity of cells. Modification of invasive capacity of T cells within tumor
is  an important  functional  deficit  induced by glioma EVs.  Lymphocyte  entry  into  brain
parenchyma is  loosely  restricted  by  the  blood-brain  barrier  and EVs  may offer  another
obstacle preventing activated T cells from accessing tumor cells.
Figure 3. PBMCs were incubated with PHA and EVs for 72 hours and intracellular signaling molecules were quanti‐
fied using protein arrays. Output from Ingenuity Pathway Analysis revealed pathways predicted to change based on
EV exposure.
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Function Predicted Activation State Z-Score
Binding of blood cells Decreased -2.000
Proliferation of T lymphocytes Decreased -2.028
Formation of cytoskeleton Decreased -2.043
Chemotaxis of cells Decreased -2.227
Adhesion of immune cells Decreased -2.323
Cytotoxicity of leukocytes Decreased -2.414
Migration of cells Decreased -3.469
Table 1. PBMCs were incubated with PHA and EVs for 2 or 72 hours, and then purified for T cells and analyzed for
intracellular signaling changes. Output from Ingenuity Pathway Analysis revealed functions predicted to change
based on protein expression. Z-score represents confidence of associated functions change.
5. Manipulation of EVs in the tumor setting
5.1. T cell rescue
GBM EVs utilize a variety of mechanisms to enhance tumor malignancy as discussed above.
However, the functional impact they have on naïve immune cells is still under investigation.
Disruption of function of naive T cells in the circulation of GBM patients may reveal a
significant barrier in production of anti-tumor responses in immunotherapy. Our data reveal
EVs alter migration pathways in T cells that have not seen tumor before, and EVs can func‐
tionally inhibit and convert naïve T-cells. However, GBM patients are not significantly globally
immune compromised and are able to mount healthy responses against communicable
diseases as well as grafted organs. This suggests specific immune tolerance to cancerous cells,
but it is not known whether cells that have been transformed by extracellular vesicles can be
rescued when challenged with a pathogen or if this is the job of truly naïve T cells. Determining
activation abilities of GBM tolerant T cells will be necessary in order to understand how to
develop new therapies to compensate for vesicle-induced modulation and to reactivate or
ablate affected cells.
5.2. EV release
Because of the known roles of EVs in propagating tumor survival, disruption of EV genesis,
release, or fusion may all offer viable solutions to lessen negative consequences of EV exposure.
In recent years, better understanding of packaging and release mechanisms have been
discovered. Some studies have been able to effectively inhibit release of EVs by inhibition of
neutral sphingomyelinases, which are necessary for EV formation [82]. Other inhibitors of
vesicle release have exhibited reduction in tumor growth in vivo, which further underlines the
importance of tumor EVs in the microenvironment [83]. Many other targets aimed to reduce
EV release are under investigation, but an obstacle in this approach is the removal of healthy
EVs as well. EVs are known to maintain homeostasis by communicating with every cell in the
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body and generating an effective immune response in a noncancerous setting. The conse‐
quences of nonselective EV removal are not understood, thus the safest inhibitor will need to
access the tumor site and selectively prevent EV release in a controlled manner. As more
evidence emerges concerning packaging and release of EVs, better targets will become
available to prevent the negative effects of tumor EV on supporting cells.
5.3. Therapeutic EVs
Engineered EVs represent a new mechanism for drug delivery and therapeutic potential in the
GBM setting. They maintain stability in circulation, protect cargo from metabolism and can
penetrate the blood-brain barrier to deliver cargo to a specific cell [41]. Their potential has not
been fully realized due to the complexity of specific binding, but it is possible in the future that
EVs will be engineered with high affinity for cellular targets. This delivery method would
provide a wide variety of benefits over antibody delivery, which has been the predominant
method of specific targeting in recent years. However, even the best targeted EV will not have
the dynamic capabilities of the natural immune system, thus EVs are under investigation as a
means to enhance the immune response against tumors. Because tumor-derived EVs contain
tumor antigen, EVs have been explored as an antigen delivery mechanism from dendritic cells
in order to prime an adaptive antitumor response. One approach that has been explored is
loading of tumor antigens onto MHC molecules on EV surfaces by pulsing dendritic cells with
tumor antigen [43]. EVs released from dendritic cells in a nontumor setting are potent
immunostimulatory agents because of their ability to express antigen, costimulatory mole‐
cules, and adhesion molecules. Artificial activation of dendritic cells must be sufficient to
produce mature cells, which express these molecules on their cell surface, in order to be
incorporated on to EV surface [84]. Full maturation of dendritic cells prior to antigen pulsing
is necessary to generate optimal antitumor responses. Once cells are loaded with antigen, EVs
can be isolated and reintroduced to the patient, or the activated dendritic cells can be injected
directly into the patient to elicit a response in vivo [69]. Studies are still under investigation to
determine the best method of transfer and optimal conditions for incubation of stimulated cells
to produce effective antitumor responses. Another approach to utilize tumor antigens within
EVs is by direct vaccination of tumor exosomes to generate specific immunity. Interestingly,
GBM EVs are not immunosuppressive in a tumor naïve setting. Prophylactic glioma EV
injection before tumor implantation in mice leads to rejection of tumor [85]. These mice exhibit
no evidence of tumor growth over time and when challenged with a second tumor implanta‐
tion, mice successfully rejected the graft again. However, EV delivered after tumor implanta‐
tion has no effect on tumor rejection. This evidence reveals potential immunostimulatory
capacity of GBM EVs in the correct setting. However, the tremendous obstacle in utilizing EVs
is that treatment for tumors must come after the tumor is established. Understanding and
mimicking the optimal environment in patients may allow for self-vaccination against their
own tumor.
5.4. Gene therapy
Gene therapy is gaining recognition as a possible avenue for future GBM treatment because
of its ability to recruit the immune system for a targeted therapy approach. It has many forms,
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ranging from virotherapy with a conditionally replicating virus to genetic immunotherapy.
By altering the genetics of target (or attack) cells, gene therapy is efficient while minimizing
detrimental systemic effects. Gene therapy employs a vector, either viral or non-viral, to deliver
genes to the cancer cells. Viral vectors are the most frequently used [86], and are being explored
in multiple glioblastoma clinical trials. An example is using a retroviral vector that codes for
an artificial molecule against a tumor-specific antigen to genetically modify T cells. The
artificial molecules are chimeric antigen receptors (CARs). Fusing an extracellular variable
domain from a high affinity monoclonal antibody specific for a tumor-associated antigen with
an intercellular signaling domain from CD3ξ of an antigen specific T cell receptor creates a
CAR. When the target antigen activates the extracellular domain, downstream signaling is
initiated to activate the T cell [87]. The survivability of viral vectors has been an issue, and
there are safety concerns with ensuring viruses are rendered non-replicative. To minimize risk
of this therapy, non-viral vectors, including EVs, are currently being explored. EVs have been
shown to be inherently capable of transferring genetic material, so using them for targeted
gene therapy is logical. Their small size, bi-lipid membrane for protecting cargo, natural, non-
viral state, capacity to be taken up by target cells, and stability during laboratory work are all
advantages [88]. It is also possible that EVs could reduce non-specific delivery and immuno‐
genicity issues. One group has been able to deliver short interfering RNA (siRNA) to disrupt
gene expression in the brain using EVs as a vehicle in order to achieve targeted gene knock‐
down. In this study, dendritic cells altered to express an EV membrane protein, Lamp2b, were
fused to neuron-specific rabies virus glycoprotein peptide 3 (RVG peptide-3). The EVs isolated
from the culture media of these cells were loaded with siRNA via electroporation, and they
were targeted to neurons with RVG-p3. Although administered systemically, the EVs were
able to specifically deliver siRNA to neurons, microglia, and oligodendrocytes in the brain and
produce gene knockdown. Moreover, the mRNA and protein levels of the gene were strongly
knocked down (approximately 60%) [89]. Recently, a group studied a non-toxic peptide-based
carrier loaded with VEGF-siRNA and BCNU, an approved chemotherapy for GBM treatment,
to target GBM cells [90]. The VEGF-siRNA and BCNU were both efficiently delivered to
cultured GBM cells, and VEGF expression was successfully reduced. The combination of gene
therapy and drugs is an exciting possibility and EVs offer an ideal mechanism of transfer as
newer therapies become available. Gene therapy is promising because it offers the opportunity
deliver novel therapies directly and efficiently into the brain. It also holds the potential for
combination therapy, such as gene therapy/engineered drug delivery with immunotherapy,
which is the most probable method for successful treatment in this complicated and unpre‐
dictable disease.
6. Conclusion
The  GBM  microenvironment  is  a  complex  and  heterogeneous  conglomeration  of  many
factors  working in  concert  to  ensure  survival  of  the  tumor.  Extracellular  vesicles  repre‐
sent a component that has not been well studied and may offer a way for GBM to exhibit
dynamic  adaptation.  Current  clinical  trials  investigate  neutralization  or  blockage  of
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individual molecules, but a single driver does not define the heterogeneous nature of GBM.
The complexity of the tumor is  likely to parallel  the complexity of its  signaling modali‐
ties. Extracellular vesicles provide transfer of discrete packets of information as a means of
influencing  countless  pathways  in  facilitation  of  tumor  progression.  Here  we  discuss
paracrine, autocrine, and immune modulatory effects of GBM-derived extracellular vesicles.
Environmental  modulation  is  necessary  for  GBM  progression  and  extracellular  vesicles
influence many of the necessary changes needed for tumor survival.  The adaptability of
GBM to tolerate toxic insults is characteristic of the tumor’s vigor. We are just now beginning
to understand the complexity of extracellular vesicle packaging to produce a tumorigenic
environment. As we understand more about the role of each signaling moiety contained
within the vesicles, more information dictating treatment can be generated based on their
overall composition. Appropriate treatment regimens will then be catered to each patient
to more efficiently target GBM cells for destruction.
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